Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
11 Juin 2024 - 10:05PM
Business Wire
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced today that
following a distinguished career, Harald Reinhart, M.D., President,
Head of Global Development, Neuroscience, Autoimmune and Infectious
Diseases (NSAiID) of Zai Lab, will retire at the end of June, after
which he will serve as a senior advisor for the Company. Rafael
Amado, M.D., President, Head of Global Oncology Research and
Development of Zai Lab, will expand his role and assume
responsibility for all of the Company’s Global R&D upon Dr.
Reinhart’s retirement.
“Harald has devoted nearly 50 years to treating patients, first
as a physician and later discovering and developing innovative
therapies to bring to patients in need around the world,” said Dr.
Samantha Du, Founder, Chairperson, and Chief Executive Officer of
Zai Lab. “Harald joined Zai Lab 10 years ago bringing his
experience in infectious diseases and later significantly expanding
the Company’s capabilities in autoimmune and neuroscience.”
Dr. Du continued, “It has been a pleasure to work alongside
Harald, and we wish him well in his retirement. He has built a
strong team and solid foundation that will continue to grow under
Rafael’s leadership.”
Dr. Reinhart said, “It’s been a great honor to work with such a
talented and dedicated team. I’m very proud of our accomplishments,
delivering and developing novel treatments in NSAiID. I look
forward to Zai’s continued success.”
As Head of Global R&D, Dr. Amado will continue to advance
Zai Lab’s existing and future pipelines across all therapy areas.
He has held senior positions and advisory roles in pharmaceutical
and biotechnology companies where he was responsible for the
discovery and development of a variety of products, across
modalities and therapeutic areas.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative,
research-based, commercial-stage biopharmaceutical company based in
China and the United States. We are focused on discovering,
developing and commercializing innovative products that address
medical conditions with significant unmet needs in the areas of
oncology, autoimmune disorders, infectious disease and
neuroscience. Our goal is to leverage our competencies and
resources to positively impact human health in China and
worldwide.
For additional information about Zai Lab, please visit
www.zailaboratory.com or follow us at
www.twitter.com/ZaiLab_Global.
Zai Lab Forward-Looking Statements
This press release contains forward-looking statements about
future expectations, plans, and prospects, including, without
limitation, statements relating to the prospects and plans for Zai
Lab’s management, operations, and growth potential. All statements,
other than statements of historical fact, included in this press
release are forward-looking statements, and can be identified by
words such as “aim,” “anticipate,” “believe,” “could,” “estimate,”
“expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,”
“potential,” “will,” “would,” and other similar expressions. Such
statements constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are not guarantees or assurances of
future performance. Forward-looking statements are based on our
expectations and assumptions as of the date of this press release
and are subject to inherent uncertainties, risks, and changes in
circumstances that may differ materially from those contemplated by
the forward-looking statements. We may not actually achieve the
plans, carry out the intentions, or meet the expectations or
projections disclosed in our forward-looking statements, and you
should not place undue reliance on these forward-looking
statements. Actual results may differ materially from those
indicated by forward-looking statements as a result of various
important factors, including but not limited to (1) our ability to
successfully commercialize and generate revenue from our approved
products, (2) our ability to obtain funding for our operations and
business initiatives, (3) the results of our clinical and
pre-clinical development of our product candidates, (4) the content
and timing of decisions made by the relevant regulatory authorities
regarding regulatory approvals of our product candidates, (5) risks
related to doing business in China, and (6) other factors
identified in our most recent annual and quarterly reports and in
other reports we have filed with the U.S. Securities and Exchange
Commission (SEC). We anticipate that subsequent events and
developments will cause our expectations and assumptions to change,
and we undertake no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise, except as may be required by law.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Our SEC filings can be found on our website at
www.zailaboratory.com and on the SEC’s website at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240611783028/en/
Investor Relations: Christine Chiou / Lina Zhang +1 (917)
886-6929 / +86 136 8257 6943 christine.chiou1@zailaboratory.com /
lina.zhang@zailaboratory.com
Media: Shaun Maccoun / Xiaoyu Chen +1 (857) 270-8854 /
+86 185 0015 5011 shaun.maccoun@zailaboratory.com /
xiaoyu.chen@zailaboratory.com
Zai Lab (NASDAQ:ZLAB)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Zai Lab (NASDAQ:ZLAB)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024